Între semaforul administrativ și timpul pacientului

The delay in the reimbursement of innovative treatments in Romania significantly impacts patients' health outcomes, leading to increased complications and mortality. Romania ranks last in the EU for access to new medications, with patients waiting over three years for treatments. The healthcare system's funding is insufficient, with public spending on medicines being among the lowest in Europe. Structural reforms are needed to accelerate access to innovative therapies and improve health outcomes. Investing in innovative medicines can yield substantial economic and social benefits, emphasizing the need for proactive public funding strategies.